Euro Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.60 M
- Company Age 29 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 96.48%
- Profit Growth 161.08%
- Ebitda 63.04%
- Net Worth 6.09%
- Total Assets 7.50%
About Euro Drugs
Euro Drugs Private Limited (EDPL) is a Private Limited Indian Non-Government Company incorporated in India on 17 February 1995 and has a history of 29 years and 11 months. Its registered office is in Delhi, India.
The Corporate was formerly known as Euro Drugs Limited. The Company is engaged in the Real Estate And Construction Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.60 M, as per Ministry of Corporate Affairs (MCA) records.
Preeti Aggarwal and Mansi Aggarwal serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U74899DL1995PTC065553
-
Company No.
065553
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
17 Feb 1995
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Euro Drugs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Preeti Aggarwal
|
Director | 17-Feb-1995 | Current |
|
Mansi Aggarwal
|
Director | 30-Oct-2014 | Current |
Financial Performance of Euro Drugs.
Euro Drugs Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 96.48% increase. The company also saw a substantial improvement in profitability, with a 161.08% increase in profit. The company's net worth moved up by a moderate rise of 6.09%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Euro Drugs?
In 2020, Euro Drugs had a promoter holding of 59.58% and a public holding of 40.42%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
La Mandre Homes LlpPreeti Aggarwal is a mutual person
-
Ga Supliers Private Limited
Preeti Aggarwal and Mansi Aggarwal are mutual person
-
Standard Brands Ltd
Preeti Aggarwal and Mansi Aggarwal are mutual person
-
Paloma Estates Private Limited
Preeti Aggarwal and Mansi Aggarwal are mutual person
-
Sea Front Structures Llp
Mansi Aggarwal is a mutual person
-
Purple Coral Homes Llp
Mansi Aggarwal is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Euro Drugs?
Unlock and access historical data on people associated with Euro Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Euro Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Euro Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
